Back to Search Start Over

CD95/Fas and metastatic disease: What does not kill you makes you stronger

Authors :
Jean Philippe Guégan
Patrick Legembre
Thomas Ducret
Pierre Vacher
Jean-François Quignard
Christophe Ginestier
Emmanuelle Charafe-Jauffret
Chemistry, Oncogenesis, Stress and Signaling (COSS)
Institut National de la Santé et de la Recherche Médicale (INSERM)-CRLCC Eugène Marquis (CRLCC)-Université de Rennes 1 (UR1)
Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)
Centre de Recherche en Cancérologie de Marseille (CRCM)
Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes
Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU)
Centre de recherche Cardio-Thoracique de Bordeaux [Bordeaux] (CRCTB)
Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Institut National de la Santé et de la Recherche Médicale (INSERM)
Actions for OnCogenesis understanding and Target Identification in ONcology (ACTION)
Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Bordeaux Segalen - Bordeaux 2-Institut Bergonié [Bordeaux]
UNICANCER-UNICANCER
INCa PLBIO
Ligue Contre le Cancer
Fondation ARC
ANR PRCE
Canceropole GO
Region Bretagne
Université de Rennes (UR)-CRLCC Eugène Marquis (CRLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Aix Marseille Université (AMU)-Institut Paoli-Calmettes
Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Institut Bergonié [Bordeaux]
UNICANCER-UNICANCER-Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM)
Source :
Seminars in Cancer Biology, Seminars in Cancer Biology, Elsevier, 2020, 60, pp.121-131. ⟨10.1016/j.semcancer.2019.06.004⟩, Seminars in Cancer Biology, 2020, 60, pp.121-131. ⟨10.1016/j.semcancer.2019.06.004⟩
Publication Year :
2020
Publisher :
HAL CCSD, 2020.

Abstract

International audience; CD95 (also known as Fas) is the prototype of death receptors; however, evidence suggests that this receptor mainly implements non-apoptotic signaling pathways such as NF-κB, MAPK, and PI3K that are involved in cell migration, differentiation, survival, and cytokine secretion. At least two different forms of CD95 L exist. The multi-aggregated transmembrane ligand (m-CD95 L) is cleaved by metalloproteases to release a homotrimeric soluble ligand (s-CD95 L). Unlike m-CD95 L, the interaction between s-CD95 L and its receptor CD95 fails to trigger apoptosis, but instead promotes calcium-dependent cell migration, which contributes to the accumulation of inflammatory Th17 cells in damaged organs of lupus patients and favors cancer cell invasiveness. Novel inhibitors targeting the pro-inflammatory roles of CD95/CD95 L may provide attractive therapeutic options for patients with chronic inflammatory disorders or cancer. This review discusses the roles of the CD95/CD95 L pair in cell migration and metastasis.

Details

Language :
English
ISSN :
1044579X and 10963650
Database :
OpenAIRE
Journal :
Seminars in Cancer Biology, Seminars in Cancer Biology, Elsevier, 2020, 60, pp.121-131. ⟨10.1016/j.semcancer.2019.06.004⟩, Seminars in Cancer Biology, 2020, 60, pp.121-131. ⟨10.1016/j.semcancer.2019.06.004⟩
Accession number :
edsair.doi.dedup.....449f3847ebf3bc2a2f1814acb6e43a73
Full Text :
https://doi.org/10.1016/j.semcancer.2019.06.004⟩